Long
Long
CCCC: When protein degradation becomes a new class of oncologyNASDAQ:CCCC
C4 Therapeutics builds a targeted protein degradation platform that destroys disease-causing proteins rather than just blocking them. A blocked protein remains in the cell and can find alternative pathways. A degraded protein ceases to exist. The company trades on Nasdaq.
Finances - Q1 2026
The report was released on May 12. Revenue came in at $6.2 million, with a net loss of $25.1 million and EPS of -$0.20. Revenue beat the analyst consensus by 39 percent, while EPS exceeded expectations by 23 percent. R&D expenses were $24.6 million, and administrative expenses were $9.3 million. Cash and marketable securities reached $268.3 million, which management estimates is sufficient to fund operations through the end of 2028. During the quarter, the company received a $2 million milestone payment from Biogen.
Cemsidomide: data that changes the narrative
At the EHA 2026 congress, the company presented updated Phase 1 results from 73 patients with relapsed or refractory multiple myeloma. At the recommended Phase 2 dose (100 mcg), the overall response rate (ORR) was 53 percent, at 75 mcg it was 40 percent, and across the entire cohort it was 36 percent.
Median duration of response reached 7.9 months, with seven patients still on treatment. In some patients, partial responses deepened over time to stringent complete responses, and two patients achieved MRD-negative status. This demonstrates not only a high response rate but also its durability in patients who had previously received a median of seven prior lines of therapy, including CAR-T and bispecific antibodies. Following the data release, the stock rose approximately 8 percent.
In parallel, the company launched the Phase 2 MOMENTUM study and a Phase 1b study in combination with elranatamab. In 2027, another combination therapy program is planned to begin.
Roche and partnership structure
In April 2026, C4 Therapeutics signed a new agreement with Roche to jointly develop degrader-antibody conjugates (DAC). The company received an upfront payment of $20 million, with potential milestone payments exceeding $1 billion across two oncology targets. Partnerships with Roche, Biogen, Betta Pharma, and Merck KGaA confirm strong interest from major pharmaceutical companies in targeted protein degradation technology.
Risks
The company remains unprofitable and fully dependent on the successful development of its clinical programs. Following the discontinuation of CFT8919 outside China, investor focus is concentrated on cemsidomide. Regulatory risks, potential toxicity in broader patient populations, and possible study delays remain key uncertainties. An additional risk is the potential capital raise through the active S-3 registration of $400 million and a $125 million ATM program.
Capital structure
Institutional investors control 78.81 percent of the company's shares. Short interest stands at 21.31 percent of the float, with Days to Cover at approximately 9.5 days. In the event of strong clinical data or new partnership agreements, this creates potential for accelerated short covering and amplified upside movement. The analyst consensus remains Strong Buy with an average price target of approximately $13.
Technicals - weekly timeframe
On the weekly chart, a clean breakout above the multi-year descending trendline has been confirmed, accompanied by a surge in accumulation volume at historical lows, indicating aggressive institutional positioning.
Indicators confirm the strength of the upward impulse. ADX has risen to 45.14, signaling the formation of a powerful trend. DI+ at 30.35 significantly exceeds DI- at 12.30, proving absolute buyer control. MACD is in an active growth phase and gives a buy signal. RSI remains in neutral territory, indicating no overheating and room for further upside.
For position entry, a full retest of the broken support zone in the 2.75–2.85 optimal entry range is recommended. The final trigger will be the formation of a golden cross. The risk-to-reward ratio at current levels looks excellent.
The first intermediate target is $10.94, with a final global target of $48.00.
C4 Therapeutics combines several strong factors: a 53 percent ORR with a 7.9-month median duration of response in heavily pretreated patients, a new Roche partnership with potential payments exceeding $1 billion, a cash runway through 2028, and short interest above 21 percent that could amplify movement on positive catalysts. 
Long
Long
SPCX / SpaceX: Waiting for Downtrend Line Breakout + Retest ConfSPCX / SpaceX Technical Analysis
SPCX failed to continue higher after the first entry area around $166 and has now broken below the previous triangle support.
Because of that, the previous short-term bullish structure should be treated as invalid for now.
On the 1H chart, price is still trading below the downtrend line, so there is no clean bullish confirmation yet.
This is not an area to average down emotionally or chase without structure.
Current key setup:
The second entry would only become interesting if price breaks above the downtrend line and completes a proper retest.
I am not waiting for price to return all the way to the previous resistance before considering the second entry.
The cleaner structure would be:
1. Break above the downtrend line
2. Retest without breaking back below it
3. Form a higher low
4. Show a clean bullish reaction after the retest
If this structure appears, the second entry setup becomes more reasonable.
If price fails to break the downtrend line and continues to get rejected, this area remains a no-trade / wait-and-see zone.
Today’s news is more positive on the surface.
Wedbush initiated coverage on SpaceX with an Outperform rating and a $190 price target, showing that some institutions still believe in the long-term SpaceX story.
However, there are still risks in the background, including valuation pressure, potential future share supply, and increasing competition in reusable rocket technology.
So the news can support sentiment, but it does not replace technical confirmation.
Current plan:
No averaging down.
No chasing without confirmation.
Wait for downtrend line breakout + retest confirmation.
Not financial advice. Just my technical analysis and trading plan. 
Short
Long
Long
Long
Short
Long
Long
The DELL Trade Is At 24R. I Did Not Predict It."Maybe I should just close it now."
"What if it gives everything back?"
"What if this is the top?"
That is the noise that comes after a trade starts paying.
As of 2026-07-14, DELL is at 24R. I bought it on 1 May at 209.60 with a stop at 200.73.
Most traders see a number like 24R and think the edge was in the prediction. It wasn't. The hard part was not finding DELL. The hard part was sitting with the open profit without turning every green candle into a new decision.
The Setup Was Simple
On 1 May, I posted two trades in my Discord. DELL was a market buy at 209.60 with a stop at 200.73. MRVL was a market buy at 161.32 with a stop at 155.75.
Nothing magical. QQQ and SPY were in clean bullish expansion. Order flow was up. I was looking for longs only. DELL was one of the names breaking out.
That was the read. Trend was up. Stock was breaking out. Risk was defined. So I entered.
The entry did not need to be clever. The stop did not need to be hidden. The setup did not need another indicator to make me feel smarter. If the trade failed, I knew where I was wrong.
That is all a setup needs to do before entry. It does not need to promise a 24R move. It cannot promise that.
Nobody Predicts 24R
This is where the lesson gets misunderstood.
I did not sit there on 1 May and say, "DELL is going to give me 24R." Nobody knows that. A good trade can stop at breakeven. A bad trade can pay for a while. A perfect looking setup can fail straight away.
The only thing I knew was this. If the market kept expanding, my rule would give the trade room. If the market broke structure, my rule would take me out.
That is not the same as predicting the final R. Prediction makes you feel smart before the trade. Rules keep you from doing stupid things after entry.
You want to know where price will go. You want certainty before you click. But the money in this trade did not come from certainty. It came from staying with uncertainty without touching the trade every time the unrealised profit moved.
The Rule Did The Holding
When I first wrote about this trade in June, I had already banked part of the position and the rest was still open.
That detail matters because 24R open is not the same as 24R fully banked. Open profit can still give back. I am not showing you this as a flex. I am showing you why the trade was able to get this far.
My rule takes profit in stages. I bank a partial when price loses the short moving average. Then I give the runner room. I close what is left only when the bigger timeframe breaks.
That breathing room is the reason a trade can run for weeks instead of dying at 5R. If you do not have an exit rule, you end up managing the trade by feeling.
Green on the screen feels fragile, so you close. Then price keeps going, so you feel stupid. Next trade, you try to hold longer. Then that one gives back, so you feel stupid again.
Back and forth. Close too early. Hold too long. Change the rule after every trade.
The rule removes that negotiation. Not perfectly. I still feel it. I still know open profit can give back. I still know I could look smart today and stupid next week. But the decision is already made before the emotion shows up.
The Same Rule Costs Me Too
Here is the part traders ignore.
A rule that lets DELL run to 24R will also make me look dumb on other trades. That is the price.
In the same basket, ARM stopped at breakeven. If I had held it manually, it would have been up around 15R at the time I wrote about it in June. But the rule said out. So I was out.
That is annoying, but it is clean. You cannot judge a rule only by the trades where it looks beautiful.
The same exit logic that gave DELL room also means I will sometimes bank less than the maximum. Sometimes I will close before a move continues. Sometimes I will watch a trade run without me.
That does not mean the rule failed. It means the rule is doing what rules do. It gives up some upside so I can keep the decision consistent across many trades.
If you change the exit every time the last trade annoys you, you do not have an exit rule. You have a memory of pain managing the next trade.
That is how you end up with random results.
Your Exit Is Probably Not A Rule Yet
Ask yourself this. Before you enter a trade, do you already know exactly how you will manage it?
Not the vague version. Not "I will let winners run." Everyone says that.
I mean the real version. Where do you take partials? When does the stop move? What must happen before the runner is closed? What would make you stay in even when the trade is already up a lot? What would make you exit even if the trade later runs without you?
If you cannot answer those before entry, you will answer them while emotional. And emotional answers change depending on the last trade.
After a loser, you close the next winner too early because you want relief. After a big winner, you hold the next one too long because you want another screenshot. After a missed runner, you give the next trade too much room because you do not want to be left behind again.
The market feels random because your management is random. The fix is not to become emotionless. The fix is to decide earlier.
Do This Before Your Next Trade
Open your journal. Take your last 10 winning trades.
For each one, write three things.
Where did you plan to take profit? Where did you actually take profit? Why did you exit there?
If the third answer is mostly feelings, you found the leak.
"It felt like enough."
"I was scared it would reverse."
"I wanted to make back last week."
"I did not want to miss another runner."
Those are not exit rules. Those are feelings with chart language on top.
My DELL trade is at 24R now because the rule did the boring part after the entry. Not because I predicted the move. Not because I was brave. Not because I knew where the top was.
The rule held the trade when my feelings would have tried to turn open profit into comfort.
If you want to review your own exits properly, use the free trade journal. Track the plan, the execution, the result and the reason you got out. Your exit rule cannot improve if your exits are just memories.
Stay consistent. Stay safe. 
Long
Long
Long
Long 
